All News

2055 articles, sorted by publication time.

Cancer Drugs · us

Pan-RAS drug shows tumor shrinkage signal in pancreatic cancer as Erasca brings forward plans for a 2027 Phase 3 trial

ERAS-0015 achieved a confirmed objective response rate of 44% in 25 previously treated patients with pancreatic cancer. These early results are driving the company to accelerate development, but more complete evidence is still needed to determine how long the effects last and whether patients receiving first-line treatment can benefit.

Biotech R&D · global

Genome & Company Joins Lilly’s TuneLab to Screen Antibody and Small-Molecule Drug Candidates with AI

From finding new targets to selecting molecules worth testing, a lengthy screening process remains. South Korea’s Genome & Company plans to connect its proprietary target discovery platform with Lilly’s predictive models to support preclinical development and technology transfer; potential time and cost savings have yet to be publicly validated.